A5064556154- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- T-cell and Retrovirus Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis C virus research
- COVID-19 epidemiological studies
- COVID-19 Pandemic Impacts
- RNA regulation and disease
- HIV/AIDS Impact and Responses
- HIV-related health complications and treatments
- HIV, Drug Use, Sexual Risk
- Syphilis Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Vector-Borne Animal Diseases
- Palliative Care and End-of-Life Issues
- Animal Disease Management and Epidemiology
- Childhood Cancer Survivors' Quality of Life
- Viral gastroenteritis research and epidemiology
- COVID-19 impact on air quality
- COVID-19 and Mental Health
- Cancer survivorship and care
- Hepatitis B Virus Studies
- Respiratory viral infections research
- Galectins and Cancer Biology
Rega Institute for Medical Research
2016-2025
KU Leuven
2014-2024
Janssen (Belgium)
2014-2018
Statistics Belgium
2012
University of Antwerp
2012
European Organisation for Research and Treatment of Cancer
2010-2011
Nephropathia epidemica (NE), an emerging rodent-borne viral disease, has become the most important cause of infectious acute renal failure in Belgium, with sharp increases incidence occurring for more than a decade. Bank voles are rodent reservoir responsible hantavirus and known to display cyclic population peaks. We tried relate these peaks NE outbreaks observed since 1993. Our hypothesis was that ecological causal connection staple food source voles, being seeds deciduous broad-leaf...
The SPREAD Programme investigated prospectively the time trend from September 2002 through December 2005 of transmitted drug resistance (TDR) among 2793 patients in 20 European countries and Israel with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection. overall prevalence TDR was 8.4% (225 2687 patients; 95% confidence interval [CI], 7.4%-9.5%), nucleoside reverse-transcriptase inhibitor (NRTI) 4.7% (125 CI, 3.9%-5.5%), nonucleoside (NNRTI) 2.3% (62 1.8%-2.9%), protease...
Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures clinical decisions. Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates transmission routes. We investigated the of in Europe Israel a representative sample patients diagnosed between 2002 2005 related it to demographic data available. 2793 PRO-RT sequences were subtyped either with REGA Subtyping tool or by manual procedure that included...
Optimal adherence to antiretroviral therapy is critical prevent HIV drug resistance (HIVDR) epidemic. The objective of the study was investigate best performing assessment method for predicting virological failure in resource-limited settings (RLS). This a single-centre prospective cohort, enrolling 220 HIV-infected adult patients attending an HIV/AIDS Care and Treatment Centre Dar es Salaam, Tanzania, 2010. Pharmacy refill, self-report (via visual analog scale [VAS] Swiss Cohort...
We investigated gender differences in treatment outcome during first line antiretroviral (ART) a hospital setting Tanzania, assessing clinical, social demographic, virological and immunological factors. conducted cohort study involving HIV infected patients scheduled to start ART followed up 1 year on ART. Structured questionnaires file review were used collect information blood was collected for CD4 viral load testing. Gender assessed using Kruskal-Wallis test chi-square continuous...
Background. Human immunodeficiency virus type 1 (HIV-1) subtype CRF01_AE originated in Africa and then passed to Thailand, where it established a major epidemic. Despite the global presence of CRF01_AE, little is known about its subsequent dispersal pattern.
One out of ten newly diagnosed patients in Europe was infected with a virus carrying drug resistant mutation. We analysed the patterns over time for transmitted resistance mutations (TDRM) using data from European Spread program. Clinical, epidemiological and virological 4317 HIV-1 infection between 2002 2007 were analysed. Patients enrolled pre-defined sampling strategy. The overall prevalence TDRM this period 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes caused by different...
Human immunodeficiency virus type 1 (HIV-1) was discovered in the early 1980s when had already established a pandemic. For at least three decades epidemic Western World has been dominated by subtype B infections, as part of sub-epidemic that traveled from Africa through Haiti to United States. However, pattern subsequent spread still remains poorly understood. Here we analyze large dataset globally representative HIV-1 strains map their around world over last 50 years and describe...
The extreme flexibility of the HIV type-1 (HIV-1) genome makes it challenging to build ideal antiretroviral treatment regimen. Interpretation HIV-1 genotypic drug resistance is evolving from rule-based systems guided by expert opinion data-driven engines developed through machine learning methods.The aim study was investigate linear and non-linear statistical models for classifying short-term virological outcome treatment. To optimize model, different feature selection methods were...
ABSTRACT Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared prevalence across subtypes A, B, C, F, G, CRF02_AG separately a cohort 3,076 patients on combination therapy including tenofovir. significantly higher subtype C. This could not be explained by demographic factors multivariate analysis, suggesting sequence-specific pathways.
Background In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends transmitted resistance mutations (TDRM) relation the risk behaviour reported. Methods HIV-1 patients newly diagnosed 27 countries from 2002 through 2007 were included. Inclusion was representative group and geographical distribution participating Europe. Trends over calculated by logistic regression. Results From 4317 included, majority...
We aimed to study epidemic trends and predictors for transmitted drug resistance (TDR) in our region, its clinical impact association with transmission clusters. included 778 patients from the AIDS Reference Center Leuven (Belgium) diagnosed 1998 2012. Resistance testing was performed using population-based sequencing TDR estimated WHO-2009 surveillance list. Phylogenetic analysis maximum likelihood Bayesian techniques. The cohort predominantly Belgian (58.4%), men who have sex (MSM)...
Despite improvements in HIV treatment, the prevalence of multidrug resistance and full class is still reported to be increasing. However, investigate whether current treatment strategies are selecting for resistance, incidence, instead prevalence, more informative. Temporal trends (MDR defined as at most 1 drug fully susceptible) (FCR no this Portugal based on 3394 viral isolates genotyped from 2000 2006 were examined using Rega 6.4.1 interpretation system. From July 2001 there was a...
To curb HIV infection rate in Tanzania, antiretroviral therapy (ART) has been scaled up since 2006, and 2019, the country shifted to regimen including dolutegravir as a default first line. We assessed success of ART contribution drug resistance (HIVDR) unsuppressed viral loads. Between February May 2023 cross-sectional survey with random sampling was conducted six clinics an urban cohort Dar es Salaam. Patients unsuppresed loads (local criteria load (VL) ≥ 1000 copies/mL) were tested for...
HTLV-1 is an enigmatic retrovirus triggering a debilitating neuroinflammatory disease, HTLV-1-associated myelopathy (HAM), with unknown pathogenesis. Both infection and HAM predominantly affect women non-white neglected populations. lacking disease-modifying treatment, as current treatment mostly symptomatic inspired by either HIV-1 or multiple sclerosis therapeutic strategies. We used systems biology analyses of novel publicly available data comprising (epi)genomics, transcriptomics,...
Abstract The genetic diversity of the HBV S gene has a significant impact on prophylaxis and treatment hepatitis B infection. effect selective pressure this alteration not yet been studied in Iranian blood donors. To explore evolution to analyze effects patterns surface antigen (HBsAg) mutations screening assays, 358 donors diagnosed as asymptomatic carriers were enrolled nationwide study. Large partial genes amplified sequenced. (sub) genotypes synonymous nonsynonymous investigated....
Background: Measurement of adherence to antiretroviral therapy (ART) can serve as a proxy for virologic failure in resource-limited settings. The aim this study was determine the factors underlying nonadherence measured by three methods. Patients and methods: This is prospective longitudinal cohort 220 patients on ART at Amana Hospital Dar es Salaam, Tanzania. We using structured questionnaire combining visual analog scale (VAS) Swiss HIV Cohort Study Adherence Questionnaire (SHCS-AQ),...
The COVID-19 pandemic has prompted a lockdown in many countries to control the exponential spread of SARS-CoV-2 virus, hereby reducing time-varying basic reproduction number (Rt) below one. Governments are looking for evidence balance demand their citizens ease some restriction, against fear new peak infections. In this study, we wanted quantify relative contribution mobility restrictions, and that behavioral changes occurred already before lockdowns, on reduction transmission during...
Abstract Background HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) is an incapacitating neuroinflammatory disorder for which no disease-modifying therapy available, but corticosteroids provide some clinical benefit. Although HAM/TSP pathogenesis not fully elucidated, older age, female sex and higher proviral load are established risk factors. We investigated systemic cytokines a novel chronic inflammatory marker, GlycA, as possible biomarkers of immunopathogenesis...
This study is the first prospective to assess prevalence, epidemiology, and risk factors of HIV-1 drug resistance in newly diagnosed HIV-infected patients Belgium. In January 2003 it was initiated as part pan-European SPREAD program, continued thereafter for four inclusion rounds until December 2006. Epidemiological, clinical, behavioral data were collected using a standardized questionnaire genotypic testing done on sample taken within 6 months diagnosis. Two hundred eighty-five included....